Tipiracil Struktur

Tipiracil

Bezeichnung:Tipiracil

CAS-Nr183204-72-0

Englisch Name:Tipiracil

CBNumberCB42666693

SummenformelC9H12Cl2N4O2

Molgewicht279.12318

MOL-Datei183204-72-0.mol

Tipiracil physikalisch-chemischer Eigenschaften

Schmelzpunkt	245℃ (decomposition)
storage temp.	2-8°C
Löslichkeit	DMSO (Slightly, Heated), Water (Slightly)
Aggregatzustand	powder
Farbe	white to beige
Stabilität	Hygroscopic

Gefahreninformationscode (GHS)

Tipiracil Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC₅₀ value of 35 nM for human placental TPase. It is selective for TPase over other pyrimidine-metabolizing enzymes (IC₅₀s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine , a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.
Verwenden
Tipiracil Hydrochloride serves as a treatment for metastatic colorectal cancer (mCRC). A thymidine phosphorylase inhibitor.
Definition
ChEBI: A hydrochloride obtained by combining tipiracil with one equivalent of hydrochloric acid. Used in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer.
Biochem/physiol Actions
Tipiracil is an inhibitor of thymidine phosphorylase. Tipiracil is used in combination with trifluridine as TAS-102 for the treatment of refractory metastatic colorectal cancer. Tipiracil increases the bioavailability of trifluridine by blocking the enzyme that would otherwise protect the tumors by metabolizing trifluridine.
target
thymidine phosphorylase
Einzelnachweise
1. tsukihara h1, nakagawa f2, sakamoto k et al. efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, tas-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. oncol rep. 2015 may;33(5):2135-42. 2. dexter dl, wolberg wh, ansfield fj, helson l and heidelberger c: the clinical pharmacology of 5-trifluoro-methyl-2'-deoxyuridine. cancer res 32: 247-253, 1972.3. fukushima m, suzuki n, emura t et al. structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. biochem pharmacol 59: 1227-1236, 2000.

Tipiracil Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

183204-72-0, Tipiracil Verwandte Suche:

Send Inquriy